11/20/2026 | Press release | Distributed by Public on 11/20/2026 19:30
|
FORM 4
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
|||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
|
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) |
4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Series G Long-Term Warrants | (3) | 11/18/2026 | X | 851,304(1) | 05/23/2024 | 05/23/2029 | Common stock, par value $0.001 per share | 9,251,513(3) | $ 0 | 13,318,344 | D | ||||
| Series H Convertible Preferred Stock | (4) | 11/18/2026 | J | 3,000(5) | (4) | 09/02/2027 | Common stock, par value $0.001 per share | 9,674,299(4) | $ 0 | 3,000 | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
|
PharmaCyte Biotech, Inc. 3960 HOWARD HUGHES PARKWAY SUITE 500 LAS VEGAS, NV 89169 |
X | |||
| PharmaCyte Biotech, Inc., By: /s/ Carlos A. Trujillo, Chief Financial Officer | 11/20/2026 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | On November 18, 2026, pursuant to a Consent and Warrant Exchange Agreement dated November 15, 2026 (the "Consent Agreement"), between PharmaCyte Biotech, Inc. (the "Reporting Person") and Q/C Technologies, Inc. (the "Issuer"), the Reporting Person exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of common stock, par value $0.001 per share of the Issuer ("Common Stock"). The number of shares of Common Stock issued was determined based on the Black Scholes value of the exchanged warrants divided by $0.3101 per share, the closing price of the Common Stock on the last trading day prior to execution of the Consent Agreement. |
| (2) | Includes 169,728 shares of Common Stock acquired as payment of Series G Dividends exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-9(a) promulgated thereunder. |
| (3) | Series G Long-Term Warrants are exercisable for shares of Common Stock at an exercise price of $0.3101 per share, subject to adjustment. |
| (4) | Each share of Series H Convertible Preferred Stock, with a stated value of $1,000, is convertible at the holder's election into approximately 3,225 shares of Common Stock, based on the current conversion price of $0.3101 per share, subject to adjustment. |
| (5) | On November 18, 2026, pursuant to the Consent Agreement, the Reporting Person consented to an amendment to the Certificate of Designations extending the maturity date of the Series H Preferred Shares from March 2, 2027 to September 2, 2027, for no additional consideration. Any deemed cancellation pursuant to the amendment is exempted by Rule 16b-6(d), and the cancellation also is exempt from reporting under Rule 16a-4(d) |